NCT05287464 International Multicentric Study ARON-1
| NCT ID | NCT05287464 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital of Macerata |
| Condition | Metastatic Renal Cell Carcinoma (mRCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,220 participants |
| Start Date | 2022-03-10 |
| Primary Completion | 2024-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,220 participants in total. It began in 2022-03-10 with a primary completion date of 2024-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
Eligibility Criteria
Inclusion Criteria: * Patients aged \>18y * Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC * Histologically or radiologically confirmed diagnosis of metastatic disease * First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab Exclusion Criteria: * Patients without histologically confirmed diagnosis of RCC * Patients without histologically or radiologically confirmed metastatic disease * Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05287464 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Renal Cell Carcinoma (mRCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05287464 currently recruiting?
Yes, NCT05287464 is actively recruiting participants. Contact the research team at mattymo@alice.it for enrollment information.
Where is the NCT05287464 trial being conducted?
This trial is being conducted at Province of Macerata, Italy.
Who is sponsoring the NCT05287464 clinical trial?
NCT05287464 is sponsored by Hospital of Macerata. The trial plans to enroll 1,220 participants.